ATE412404T1 - Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon - Google Patents
Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davonInfo
- Publication number
- ATE412404T1 ATE412404T1 AT04735713T AT04735713T ATE412404T1 AT E412404 T1 ATE412404 T1 AT E412404T1 AT 04735713 T AT04735713 T AT 04735713T AT 04735713 T AT04735713 T AT 04735713T AT E412404 T1 ATE412404 T1 AT E412404T1
- Authority
- AT
- Austria
- Prior art keywords
- buprenorphine
- salt
- oral pharmaceutical
- pharmaceutical compositions
- stable oral
- Prior art date
Links
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title abstract 3
- 229960001736 buprenorphine Drugs 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000008203 oral pharmaceutical composition Substances 0.000 title 1
- 239000003963 antioxidant agent Substances 0.000 abstract 2
- 230000003078 antioxidant effect Effects 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/BE2004/000081 WO2005117838A1 (en) | 2004-06-02 | 2004-06-02 | Stable oral pharmaceutical compositions of buprenorphine and derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE412404T1 true ATE412404T1 (de) | 2008-11-15 |
Family
ID=34957905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04735713T ATE412404T1 (de) | 2004-06-02 | 2004-06-02 | Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1750675B1 (de) |
| AT (1) | ATE412404T1 (de) |
| DE (1) | DE602004017514D1 (de) |
| WO (1) | WO2005117838A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140271788A1 (en) | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| DK2001456T3 (da) * | 2006-04-04 | 2010-04-12 | Emodys Gmbh | Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser |
| GB2461681A (en) * | 2008-04-17 | 2010-01-13 | Pharmasol Ltd | Buprenorphine liquid spray formulation with solvent and antioxidant |
| US8491937B2 (en) * | 2007-02-15 | 2013-07-23 | Wyeth Llc | Stability in vitamin and mineral supplements |
| GB2450117A (en) * | 2007-06-13 | 2008-12-17 | Reckitt Benckiser Healthcare | A water- and oxygen-occlusive blister tablet pack |
| AU2013245546C1 (en) * | 2011-09-19 | 2017-08-24 | Orexo Ab | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
| EP2915525B1 (de) | 2011-09-19 | 2021-08-11 | Orexo AB | Mißbrauchssichere Sublingualtabletten enthaltend Buprenorphin und Naloxon |
| EP2983668A4 (de) * | 2013-04-08 | 2017-01-11 | Virginia Commonwealth University | Zusammensetzungen zur erleichterung des präsystemischen metabolismus von opioiden |
| RU2635993C1 (ru) * | 2016-09-09 | 2017-11-17 | Закрытое акционерное общество "Научно-производственное объединение "ДОМ ФАРМАЦИИ" | Композиция убихинола для парентерального введения и способ её получения |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1302682B1 (it) * | 1998-10-16 | 2000-09-29 | Formenti Farmaceutici Spa | Composizioni farmaceutiche orali contenenti buprenorfina |
| GB0214147D0 (en) * | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Formulations |
-
2004
- 2004-06-02 EP EP04735713A patent/EP1750675B1/de not_active Expired - Lifetime
- 2004-06-02 WO PCT/BE2004/000081 patent/WO2005117838A1/en not_active Ceased
- 2004-06-02 AT AT04735713T patent/ATE412404T1/de not_active IP Right Cessation
- 2004-06-02 DE DE602004017514T patent/DE602004017514D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005117838A1 (en) | 2005-12-15 |
| EP1750675A1 (de) | 2007-02-14 |
| EP1750675B1 (de) | 2008-10-29 |
| DE602004017514D1 (de) | 2008-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
| MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
| NO20051102L (no) | Sulfonylamino-eddiksyre-derivater | |
| ATE486587T1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
| TW200633716A (en) | Compositions and methods for stabilizing active pharmaceutical ingredients | |
| ATE286500T1 (de) | 1,2,3,4-tetrahydroisochinolin-derivate | |
| DK1157037T3 (da) | GCSF-konjugater | |
| SE0401971D0 (sv) | Piperidne derivatives | |
| CY1110664T1 (el) | Ενδορινικες συνθεσετς | |
| NO20042844L (no) | 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister | |
| UA94065C2 (en) | Dihydropseudoerythromycin derivatives | |
| TR200401793T4 (tr) | Perindopril tuzu ve bunu içeren farmasötik bileşimler. | |
| PT1121127E (pt) | Composicoes farmaceuticas orais contendo buprenorfina | |
| UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
| IL164440A0 (en) | New pharmaceutical composition containing fibanserin polymorph a | |
| MY140630A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| ATE528009T1 (de) | Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten | |
| MY147373A (en) | Piperazine derivatives as antimalarial agents | |
| ATE412404T1 (de) | Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon | |
| TW200626581A (en) | Compounds, compositions containing them, preparation thereof and uses thereof | |
| IS8334A (is) | Æxilseyðandi samsetningar sem samanstanda af defíbrótíði stöku eða blönduðu með öðrum æxliseyðandi miðlum | |
| NZ523606A (en) | Pharmaceutical compositions and methods for use | |
| EA200601015A1 (ru) | Пероральные композиции дезоксипеганина и их применение | |
| MXPA04005033A (es) | Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes. | |
| ATE460934T1 (de) | Pharmazeutische zubereitungen von ciprofloxacin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |